author-photo

X. Liu

Academy of Military Medical Sciences

19

Papers

4009

Citations

Citation Trend

Filter By

Papers (19) Sort By

Journal Conference Others

P109 Combined Chemotherapy Versus Topotecan Monotherapy as Second-Line Treatment for Patients with Sensitive Relapsed SCLC

2018 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
P110 Disparities of EGFR Mutations Between Biopsy and Rebiopsy in Non-Small Cell Lung Cancer Patients

2018 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study

2017 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (122)
P2.04-003 Phase II Trial of X-396 (Ensartinib) for Chinese Patients with ALK (+) Non–Small-Cell Lung Cancer Who Progressed on Crizotinib

2017 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Characteristics and prognostic potential of tertiary lymphoid structures in oral tongue squamous cell carcinoma

2016 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Continuation of afatinib (A) beyond progression: results of a randomized, open-label, phase III trial of A plus paclitaxel (P) versus investigator's choice chemotherapy (CT) in patients (pts) with metastatic non-small-cell lung cancer (NSCLC) progressed on erlotinib/gefitinib (E/G) and A: LUX-Lung 5 (LL5)

2015 Pneumologie
Show All
- Source
- Cite
- Save
Citations (2)
Final overall survival results from a randomised, Phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)

2015 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (279)
First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study

2015 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (432)
Efficacy and Biomarker Data From BEYOND: A Randomized Phase 3 Study of First-Line Chemotherapy ± Bevacizumab in Chinese Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer

2014 International Journal of Radiation Oncology Biology Physics
Show All
- Source
- Cite
- Save
Citations (0)
1265PPATIENT-REPORTED OUTCOMES (PROS) IN PATIENTS (PTS) WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) RECEIVING AFATINIB (A) MONOTHERAPY FOLLOWED BY A + PACLITAXEL (A + P) VS INVESTIGATOR'S CHOICE OF SINGLE-AGENT CHEMOTHERAPY (IC): LUX-LUNG 5 (LL5)

2014 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (4)